Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Conference Roundup > Registry study shows MIGS for secondary glaucoma is failure-free for most at nearly 2 years
  • Conference Roundup

Registry study shows MIGS for secondary glaucoma is failure-free for most at nearly 2 years

Ophthalmology 360

David Friedman, MD, PhD, MPH, and co-author, Asahi Fujita, MD, both of Mass Eye and Ear, detailed findings from their registry study presented at the AGS 2026 Annual Meeting. They found that trying less invasive surgery first in patients with secondary glaucoma could be an option for this patient population.

Asahi Fujita, MD:

In this paper, using the IRIS Registry, which is a nationwide ophthalmic registry, we evaluated the outcomes of glaucoma surgeries among young adults with secondary glaucoma. We did this research because the outcomes of glaucoma surgeries among this population has not been investigated very well. That’s why we did this. We included 2,500 eyes, and we defined failure as having either 1 of the following criteria: number 1, insufficient IOP reduction; number 2, hypotony; number 3, additional IOP-lowering surgeries; and number 4, development of no light perception. We found that, among eyes with steroid-induced glaucoma, two-thirds of the eyes remained failure-free following trabeculectomy, but about 10% of those eyes experienced hypotony. MIGS has been considered as less effective for traumatic glaucoma, but in our analysis, about half of the eyes remained failure-free at 2 years.

David Friedman, MD, PhD, MPH:

That was also true with steroid-induced glaucomas. We were able to get decent pressure lowering, at least for a couple of years, in many of these other forms of secondary glaucoma, such as steroid-induced, traumatic. I think what we found here gives an option and shows that it can work to trying less invasive surgery first in some of these secondary glaucomas where some people tend to think they won’t work, and that was, I think, an important finding. We need to extend it for longer time to see how long we can get. But certainly, it can buy a few years, which is highly valuable to the patient, right?

Asahi Fujita, MD:

Yes. Even though trabeculectomy is effective in reducing IOP, it sometimes causes hypotony, so we have to be careful about that.

David Friedman, MD, PhD, MPH:

Yeah. These secondary glaucomas are probably at higher risk of hypotony because they start at such a high pressure, and if you allow too much out too quickly, you can get very low pressures.

Share

Related Content

  • The Interventional Glaucoma Project

Improving Patient Experience and Practice Workflow With an Interventional Glaucoma Approach

  • The Interventional Glaucoma Project

Data-Driven Focus on Interventional Glaucoma Care

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Conference Roundup

Enhanced monofocal IOLs provide better intermediate vision with no rings or dysphotopsia

  • Conference Roundup

Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial dysfunction

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon